Abstract |
The efficacy and safety of sulfasalazine for the treatment of juvenile spondyloarthropathy were evaluated in an open study. Twenty-three patients (17 boys and 6 girls) with juvenile spondyloarthropathy inadequately controlled by nonsteroidal antiinflammatory therapy were given sulfasalazine in an average dosage of 39 mg/kg/d. After 3 months, 20 patients exhibited marked clinical improvement; of these 20, 14 discontinued or reduced their nonsteroidal antiinflammatory drug. Mean erythrocyte sedimentation rate fell significantly from 36.8 to 13.7 mm/h. After 12 months. 78% of the patients were in remission. Sulfasalazine was stopped in five patients of which none had evidence of disease relapse 6 to 12 months later. Side effects were infrequent: 2 patients had a skin rash requiring drug withdrawal and two developed mild neutropenia. These data suggest that sulfasalazine is an effective and safe second-line drug for the management of severe juvenile spondyloarthropathies.
|
Authors | C Job-Deslandre, C J Menkès |
Journal | Revue du rhumatisme (Ed. francaise : 1993)
(Rev Rhum Ed Fr)
1993 Jul-Sep
Vol. 60
Issue 7-8
Pg. 489-91
ISSN: 1169-8330 [Print] France |
Vernacular Title | Traitement des spondyloarthropathies juvéniles par la sulfasalazine. |
PMID | 7908584
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Arthritis, Juvenile
(drug therapy)
- Child
- Child, Preschool
- Chronic Disease
- Female
- Follow-Up Studies
- Humans
- Joint Diseases
(drug therapy)
- Male
- Spondylitis
(drug therapy)
- Sulfasalazine
(therapeutic use)
- Treatment Outcome
|